Cancer researchers have always understood the power of combination therapies—blending two or more drugs together to fight the heterogeneous nature of tumors has helped...
Merck & Co. said today it has agreed to acquire Immune Design for approximately $300 million, in a deal designed to boost the buyer’s...
Eli Lilly will pay AC Immune CHF 30 million ($30.2 million) in the first milestone payment tied to the companies’ CHF 1.89 billion ($1.9 billion) collaboration launched in December to develop new treatments for Alzheimer’s disease and other neurodegenerative disorders, the Swiss biotech said.
Screening library and drug discovery services provider will supply library synthesis, medicinal chemistry, and biological services for EMBL's small-molecule cancer therapeutics program
Challenges remain in cell therapy manufacturing optimization and scalability, especially when developing autologous therapies. In a recent GEN webinar, Matthew Hewitt, PhD, head of R&D and clinical development, personalized medicine at Lonza, and Stacey Willard, PhD, director of product management at IsoPlexis, provided an overview of the Cocoon™ cell therapy manufacturing platform and the IsoLight™ single-cell proteomics system along with data from case studies.
Researchers from Boston University School of Medicine have discovered the protein c-Cbl has the ability to degrade checkpoint protein PD-1, a protein found on T cells that helps keep them from attacking other cells in the body. Manipulating c-Cbl's ability to regulate expression of PD-1 may be beneficial in the treatment of certain cancers including melanoma, bladder, kidney, breast, and non-small lung cancers.
Monovalent and bivalent vaccines both miss primary endpoint of reducing viral shedding in HSV-2 infected patients
The Series B round was led by Lilly Ventures, with participation from Novartis Option Fund and Bio*One Capital of Singapore. Cubist Pharmaceuticals also joined.
Proof-of-concept study shows that C-H functionalization can selectively modify natural products such as alkaloids, possibly accelerating drug discovery.